Angiogenesis and epidermal growth factor receptor inhibitors in non-small cell lung cancer
Several preclinical studies suggested a potential benefit from combined treatment with inhibitors of epidermal growth factor receptor (EGFR) and angiogenesis, both effective in patients with advanced non-small-cell lung cancer (NSCLC). In pretreated patients with advanced EGFR wild type NSCLC, bevac...
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Open Exploration Publishing Inc.
2020-04-01
|
| Series: | Exploration of Targeted Anti-tumor Therapy |
| Subjects: | |
| Online Access: | https://www.explorationpub.com/Journals/etat/Article/10028 |
| _version_ | 1830199989653995520 |
|---|---|
| author | Giuliano Palumbo Giovanna Esposito Guido Carillio Anna Manzo Agnese Montanino Vincenzo Sforza Raffaele Costanzo Claudia Sandomenico Carmine La Manna Nicola Martucci Antonello La Rocca Giuseppe De Luca Maria Carmela Piccirillo Rossella De Cecio Francesco Perrone Giuseppe Totaro Paolo Muto Carmine Picone Nicola Normanno Alessandro Morabito |
| author_facet | Giuliano Palumbo Giovanna Esposito Guido Carillio Anna Manzo Agnese Montanino Vincenzo Sforza Raffaele Costanzo Claudia Sandomenico Carmine La Manna Nicola Martucci Antonello La Rocca Giuseppe De Luca Maria Carmela Piccirillo Rossella De Cecio Francesco Perrone Giuseppe Totaro Paolo Muto Carmine Picone Nicola Normanno Alessandro Morabito |
| author_sort | Giuliano Palumbo |
| collection | DOAJ |
| description | Several preclinical studies suggested a potential benefit from combined treatment with inhibitors of epidermal growth factor receptor (EGFR) and angiogenesis, both effective in patients with advanced non-small-cell lung cancer (NSCLC). In pretreated patients with advanced EGFR wild type NSCLC, bevacizumab plus erlotinib improved progression-free survival as second-line therapy in the BeTa study and as maintenance therapy in the ATLAS trial, although the benefit was modest and did not translate into an advantage in overall survival. Disappointing results were reported with oral VEGF inhibitors plus erlotinib in pretreated patients with EGFR wild type NSCLC. On the contrary, erlotinib plus bevacizumab or ramucirumab showed a clinically relevant improvement of progression-free survival in naïve patients with EGFR mutations, leading to the approval of these two regimens as first-line treatment of NSCLC patients with EGFR mutant tumors. Several clinical studies are evaluating the feasibility and activity of osimertinib plus bevacizumab or ramucirumab. However, limits that could affect its use in clinical practice are the need of an intravenous infusion for angiogenesis inhibitors, the increased incidence of treatment associated adverse events, the exclusion of patients with tumors located in central position or at risk of hemorrhage. The identification of predictive biomarkers is an important goal of research to optimize the combined use of these agents. |
| first_indexed | 2024-12-18T02:24:40Z |
| format | Article |
| id | doaj.art-c82f4a7e219749f59ba316d6d80fa07c |
| institution | Directory Open Access Journal |
| issn | 2692-3114 |
| language | English |
| last_indexed | 2024-12-18T02:24:40Z |
| publishDate | 2020-04-01 |
| publisher | Open Exploration Publishing Inc. |
| record_format | Article |
| series | Exploration of Targeted Anti-tumor Therapy |
| spelling | doaj.art-c82f4a7e219749f59ba316d6d80fa07c2022-12-21T21:24:04ZengOpen Exploration Publishing Inc.Exploration of Targeted Anti-tumor Therapy2692-31142020-04-011211713010.37349/etat.2020.00008Angiogenesis and epidermal growth factor receptor inhibitors in non-small cell lung cancerGiuliano Palumbo0Giovanna Esposito1Guido Carillio2Anna Manzo3Agnese Montanino4Vincenzo Sforza5Raffaele Costanzo6Claudia Sandomenico7Carmine La Manna8Nicola Martucci9Antonello La Rocca10Giuseppe De Luca11Maria Carmela Piccirillo12Rossella De Cecio13Francesco Perrone14Giuseppe Totaro15Paolo Muto16Carmine Picone17Nicola Normanno18https://orcid.org/0000-0002-7158-2605Alessandro Morabito19https://orcid.org/0000-0002-1319-9608Department of Oncology, Ospedale S. Maria della Pietà, Casoria, 80026 Napoli, ItalyThoracic Medical Oncology, Istituto Nazionale Tumori “Fondazione G. Pascale”-IRCCS, 80131 Napoli, ItalyDepartment of Oncology & Hematology, Azienda Ospedaliera Pugliese-Ciaccio, 88100 Catanzaro, ItalyThoracic Medical Oncology, Istituto Nazionale Tumori “Fondazione G. Pascale”-IRCCS, 80131 Napoli, ItalyThoracic Medical Oncology, Istituto Nazionale Tumori “Fondazione G. Pascale”-IRCCS, 80131 Napoli, ItalyThoracic Medical Oncology, Istituto Nazionale Tumori “Fondazione G. Pascale”-IRCCS, 80131 Napoli, ItalyThoracic Medical Oncology, Istituto Nazionale Tumori “Fondazione G. Pascale”-IRCCS, 80131 Napoli, ItalyThoracic Medical Oncology, Istituto Nazionale Tumori “Fondazione G. Pascale”-IRCCS, 80131 Napoli, ItalyThoracic Surgery, Istituto Nazionale Tumori “Fondazione G. Pascale”-IRCCS, 80131 Naples, ItalyThoracic Surgery, Istituto Nazionale Tumori “Fondazione G. Pascale”-IRCCS, 80131 Naples, ItalyThoracic Surgery, Istituto Nazionale Tumori “Fondazione G. Pascale”-IRCCS, 80131 Naples, ItalyThoracic Surgery, Istituto Nazionale Tumori “Fondazione G. Pascale”-IRCCS, 80131 Naples, ItalyClinical Trials Unit, Istituto Nazionale Tumori “Fondazione G. Pascale”-IRCCS, 80131 Naples, ItalyPathology, Istituto Nazionale Tumori “Fondazione G. Pascale”-IRCCS, 80131 Naples, ItalyClinical Trials Unit, Istituto Nazionale Tumori “Fondazione G. Pascale”-IRCCS, 80131 Naples, ItalyRadiotherapy, Istituto Nazionale Tumori “Fondazione G. Pascale”, IRCCS, 80131 Naples, ItalyRadiotherapy, Istituto Nazionale Tumori “Fondazione G. Pascale”, IRCCS, 80131 Naples, ItalyRadiology, Istituto Nazionale Tumori “Fondazione G. Pascale”- IRCCS, 80131 Naples, ItalyCellular Biology and Biotherapy, Istituto Nazionale Tumori “Fondazione G. Pascale”-IRCCS, 80131 Naples, ItalyThoracic Medical Oncology, Istituto Nazionale Tumori “Fondazione G. Pascale”-IRCCS, 80131 Napoli, ItalySeveral preclinical studies suggested a potential benefit from combined treatment with inhibitors of epidermal growth factor receptor (EGFR) and angiogenesis, both effective in patients with advanced non-small-cell lung cancer (NSCLC). In pretreated patients with advanced EGFR wild type NSCLC, bevacizumab plus erlotinib improved progression-free survival as second-line therapy in the BeTa study and as maintenance therapy in the ATLAS trial, although the benefit was modest and did not translate into an advantage in overall survival. Disappointing results were reported with oral VEGF inhibitors plus erlotinib in pretreated patients with EGFR wild type NSCLC. On the contrary, erlotinib plus bevacizumab or ramucirumab showed a clinically relevant improvement of progression-free survival in naïve patients with EGFR mutations, leading to the approval of these two regimens as first-line treatment of NSCLC patients with EGFR mutant tumors. Several clinical studies are evaluating the feasibility and activity of osimertinib plus bevacizumab or ramucirumab. However, limits that could affect its use in clinical practice are the need of an intravenous infusion for angiogenesis inhibitors, the increased incidence of treatment associated adverse events, the exclusion of patients with tumors located in central position or at risk of hemorrhage. The identification of predictive biomarkers is an important goal of research to optimize the combined use of these agents.https://www.explorationpub.com/Journals/etat/Article/10028lung cancerangiogenesistyrosine kinase inhibitorerlotinibbevacizumab |
| spellingShingle | Giuliano Palumbo Giovanna Esposito Guido Carillio Anna Manzo Agnese Montanino Vincenzo Sforza Raffaele Costanzo Claudia Sandomenico Carmine La Manna Nicola Martucci Antonello La Rocca Giuseppe De Luca Maria Carmela Piccirillo Rossella De Cecio Francesco Perrone Giuseppe Totaro Paolo Muto Carmine Picone Nicola Normanno Alessandro Morabito Angiogenesis and epidermal growth factor receptor inhibitors in non-small cell lung cancer Exploration of Targeted Anti-tumor Therapy lung cancer angiogenesis tyrosine kinase inhibitor erlotinib bevacizumab |
| title | Angiogenesis and epidermal growth factor receptor inhibitors in non-small cell lung cancer |
| title_full | Angiogenesis and epidermal growth factor receptor inhibitors in non-small cell lung cancer |
| title_fullStr | Angiogenesis and epidermal growth factor receptor inhibitors in non-small cell lung cancer |
| title_full_unstemmed | Angiogenesis and epidermal growth factor receptor inhibitors in non-small cell lung cancer |
| title_short | Angiogenesis and epidermal growth factor receptor inhibitors in non-small cell lung cancer |
| title_sort | angiogenesis and epidermal growth factor receptor inhibitors in non small cell lung cancer |
| topic | lung cancer angiogenesis tyrosine kinase inhibitor erlotinib bevacizumab |
| url | https://www.explorationpub.com/Journals/etat/Article/10028 |
| work_keys_str_mv | AT giulianopalumbo angiogenesisandepidermalgrowthfactorreceptorinhibitorsinnonsmallcelllungcancer AT giovannaesposito angiogenesisandepidermalgrowthfactorreceptorinhibitorsinnonsmallcelllungcancer AT guidocarillio angiogenesisandepidermalgrowthfactorreceptorinhibitorsinnonsmallcelllungcancer AT annamanzo angiogenesisandepidermalgrowthfactorreceptorinhibitorsinnonsmallcelllungcancer AT agnesemontanino angiogenesisandepidermalgrowthfactorreceptorinhibitorsinnonsmallcelllungcancer AT vincenzosforza angiogenesisandepidermalgrowthfactorreceptorinhibitorsinnonsmallcelllungcancer AT raffaelecostanzo angiogenesisandepidermalgrowthfactorreceptorinhibitorsinnonsmallcelllungcancer AT claudiasandomenico angiogenesisandepidermalgrowthfactorreceptorinhibitorsinnonsmallcelllungcancer AT carminelamanna angiogenesisandepidermalgrowthfactorreceptorinhibitorsinnonsmallcelllungcancer AT nicolamartucci angiogenesisandepidermalgrowthfactorreceptorinhibitorsinnonsmallcelllungcancer AT antonellolarocca angiogenesisandepidermalgrowthfactorreceptorinhibitorsinnonsmallcelllungcancer AT giuseppedeluca angiogenesisandepidermalgrowthfactorreceptorinhibitorsinnonsmallcelllungcancer AT mariacarmelapiccirillo angiogenesisandepidermalgrowthfactorreceptorinhibitorsinnonsmallcelllungcancer AT rosselladececio angiogenesisandepidermalgrowthfactorreceptorinhibitorsinnonsmallcelllungcancer AT francescoperrone angiogenesisandepidermalgrowthfactorreceptorinhibitorsinnonsmallcelllungcancer AT giuseppetotaro angiogenesisandepidermalgrowthfactorreceptorinhibitorsinnonsmallcelllungcancer AT paolomuto angiogenesisandepidermalgrowthfactorreceptorinhibitorsinnonsmallcelllungcancer AT carminepicone angiogenesisandepidermalgrowthfactorreceptorinhibitorsinnonsmallcelllungcancer AT nicolanormanno angiogenesisandepidermalgrowthfactorreceptorinhibitorsinnonsmallcelllungcancer AT alessandromorabito angiogenesisandepidermalgrowthfactorreceptorinhibitorsinnonsmallcelllungcancer |